
|Videos|May 31, 2017
Dr. Hayes Discusses Anti-Estrogen Therapy Beyond 5 Years in Breast Cancer
Author(s)Daniel F. Hayes, MD
Daniel F. Hayes, MD, professor of University of Michigan Comprehensive Cancer Center, discusses anti-estrogen therapy beyond 5 years in breast cancer.
Advertisement
Daniel F. Hayes, MD, professor of University of Michigan Comprehensive Cancer Center, discusses anti-estrogen therapy beyond 5 years in breast cancer.
One of the big questions facing the breast cancer field, Hayes says, is what to do about women who have made it to 5 years on an anti-estrogen therapy.
There are now 4 trials to suggest that continued anti-estrogen therapy beyond 5 years suppresses late recurrence.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5



































